Table 1.
Patient demographics and baseline characteristics (intention to treat population).
| SR paracetamol (n = 203) | IR paracetamol (n = 200) | |
|---|---|---|
| Age (years) | ||
| Median | 65.2 | 65.4 |
| Range | 30.1–80.9 | 33.6–80.9 |
| Gender | ||
| Male | 79 (38.9%) | 75 (37.5%) |
| Female | 124 (61.1%) | 125 (62.5%) |
| Race | ||
| Caucasian | 202 (99.5%) | 196 (98.0%) |
| Black | 1 (0.5%) | 2 (1.0%) |
| Asian | 0 | 1 (0.5%) |
| Other | 0 | 1 (0.5%) |
| Weight (kg) | ||
| Mean | 83.16 | 81.46 |
| s.d. | 17.00 | 15.90 |
| Two most common concomitant medications* | ||
| Analgesics | 98 (48.3%) | 86 (43.0%) |
| Anti-inflammatory/ antirheumatic | 73 (36.0%) | 75 (37.5%) |
| Two most common medical histories*† | ||
| Cardiovascular | 100 (49.3%) | 95 (47.5%) |
| Genitourinary | 71 (35.0%) | 78 (39.0%) |
Prior to start of run-in phase.
Body system names (excluding musculoskeletal disorders).